Shionogi is a research-driven pharmaceutical company focused on discovering, developing, and commercializing innovative medicines to address unmet medical needs. The company emphasizes a strong commitment to infectious diseases, particularly in the fight against antimicrobial resistance (AMR), and aims to deliver value through patient-centered innovation.
Rooted in a long-term business strategy, Shionogi strengthens its R&D capabilities through open innovation, digital therapies, and investigator-initiated research. The company operates globally, guided by its core philosophy of placing patients first and contributing to public health through responsible and sustainable practices.
Shionogi also prioritizes corporate governance, compliance, and sustainability, integrating these principles into its operations. The company actively engages stakeholders and promotes access to healthcare, ethical standards, and environmental responsibility as part of its mission to be a meaningful force in society.